Health
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif., May 19, 2026--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2 in Chicago.
About this update from Roche Holding Ltd
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":952,"height":226,"url":"https://media.zenfs.com/en/business-wire.com/66efbac21fdb4320d548229e4a3fa648"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4YErJotGaMg8f9oixWPTKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyOA--/https://media.zenfs.com/en/business-wire.com/66efbac21fdb4320d548229e4a3fa648","width":952,"height":226},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/9BTPcJXsAzMBkXx8EUv4HA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE1Mg--/https://media.zenfs.com/en/business-wire.com/66efbac21fdb4320d548229e4a3fa648","width":640,"height":152},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/52AkVbdaRitFXLTv987Rhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE5MDQ7aD00NTI-/https://media.zenfs.com/en/business-wire.com/66efbac21fdb4320d548229e4a3fa648","width":952,"height":226}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages","length":154,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Primary results from the persevERA study on the numerical improvement in progression-free survival observed with first-line giredestrant plus palbociclib in advanced, endocrine-sensitive disease","length":194,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Overall, nine approved and investigational medicines, including bispecific antibodies, antibody-drug conjugates and brain-permeable molecules, with ASCO data targeting urgent needs in breast, blood, lung and other cancers","length":221,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":569,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 19, 2026--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2 in Chicago.","length":338,"tagName":"p"},{"type":"text","content":""Genentech’s ASCO data reflect our commitment to addressing those cancers that impose the highest burden on patients and society,...